Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LPL | P06858 | 1/20 | 0.34 |
| ▸ | LIPG | Q9Y5X9 | 1/20 | 0.34 |
| ▸ | EGFR | P00533 | 2/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | CD44 | P16070 | 1/20 | 0.31 |
| ▸ | JAK2 | O60674 | 2/20 | 0.30 |
| ▸ | BTK | Q06187 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14790572 | 1.00 | LPL (0.34) | LPLLIPGEGFRGAAALDH1A1 | |
| SCHEMBL30296224 | 1.00 | LPL (0.34) | LPLLIPGEGFRGAAALDH1A1 | |
| SCHEMBL25421760 | 0.93 | LPL (0.34) | LPLLIPGEGFRALDH1A1JAK2 | |
| SCHEMBL18350270 | 0.87 | EGFR (0.36) | LPLLIPGEGFRGAACD44 | |
| SCHEMBL27192332 | 0.86 | LPL (0.38) | LPLLIPGEGFRJAK2BTK | |
| SCHEMBL59040 | 0.84 | LPL (0.37) | LPLLIPGALDH1A1JAK2BTK | |
| SCHEMBL29385065 | 0.84 | LPL (0.37) | LPLLIPGALDH1A1JAK2BTK | |
| SCHEMBL5504723 | 0.81 | CD44 (0.39) | GAAALDH1A1CD44JAK2BTK | |
| SCHEMBL58364 | 0.81 | LPL (0.35) | LPLLIPGALDH1A1JAK2BTK | |
| SCHEMBL15289502 | 0.81 | LPL (0.37) | LPLLIPGALDH1A1JAK2BTK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4702021-A1 | COMPOUNDS CAPABLE OF MODULATING GPR65 | Pathios Therapeutics Limited (GB) | 2026-03-04 | — | — | EP | disclosed |
| US-20240368173-A1 | TRICYCLIC GPR65 MODULATORS | Pathios Therapeutics Limited (GB) | 2024-11-07 | — | — | US | disclosed |
| WO-2024224064-A1 | COMPOUNDS CAPABLE OF MODULATING GPR65 | Pathios Therapeutics Limited (GB) | 2024-10-31 | — | — | WO | disclosed |
| EP-4419203-A1 | TRICYCLIC GPR65 MODULATORS | Pathios Therapeutics Limited (GB) | 2024-08-28 | — | — | EP | disclosed |
| WO-2023067322-A1 | TRICYCLIC GPR65 MODULATORS | Pathios Therapeutics Limited (GB) | 2023-04-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240368173-A1 | TRICYCLIC GPR65 MODULATORS | GPR65, GPR3, NR1H2 | LPL 1411/4885LIPG 3094/4885EGFR 353/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.